Streetbeat News

Earnings

GD

General Dynamics is maintaining a strong performance despite delays in G700 deliveries, with significant growth in aerospace and positive revenue and margin projections.

Portfolio Pulse from

December 03, 2024 | 4:15 am

PROSY

Prosus CEO Fabricio Bloisi discusses the company's earnings and anticipates an increase in IPOs in India in the coming months.

Portfolio Pulse from

December 03, 2024 | 3:30 am

ADBE

Adobe's Q3 results exceeded expectations, but the stock dipped due to soft guidance. The Firefly AI platform shows promise, and despite mixed valuation metrics, Adobe's PEG ratio suggests undervaluation. Key risks include competition and macroeconomic downturns.

Portfolio Pulse from

December 03, 2024 | 2:00 am

CRDO

Credo Technology Group Holding Ltd (CRDO) held its Q2 2025 earnings call, discussing financial performance and future outlook with analysts from major financial institutions.

Portfolio Pulse from

December 03, 2024 | 2:00 am

ZS

Zscaler, Inc. held its Q1 2025 earnings call, discussing financial performance and strategic insights with various analysts from major financial institutions.

Portfolio Pulse from

December 03, 2024 | 2:00 am

PLTR

Palantir Technologies is experiencing a significant increase in stock value, with a 285% return year to date, driven by growth and profitability. The company is seen as an AI innovator with potential for global expansion.

Portfolio Pulse from

December 03, 2024 | 1:30 am

CLSK

CleanSpark, Inc. (CLSK) held its Q4 2024 earnings conference call, discussing financial results and company performance. Key participants included CEO Zach Bradford and CFO Gary Vecchiarelli, with analysts from HC Wainwright, Clear Street, BTIG, Cantor Fitzgerald, and JPMorgan attending.

Portfolio Pulse from

December 03, 2024 | 12:45 am

ZS

Economic data for manufacturing and construction was positive, but Zscaler (ZS) experienced a sell-off despite beating Q1 estimates.

Portfolio Pulse from

December 03, 2024 | 12:15 am

FIVN

Five9 (FIVN) has a consensus price target indicating a potential 25.2% upside. Despite skepticism about the effectiveness of price targets, positive earnings estimate revisions suggest a possible near-term stock price increase.

Portfolio Pulse from

December 03, 2024 | 12:00 am

URGN

Wall Street analysts have set a mean price target for Urogen Pharma (URGN) that suggests a potential 209.9% upside. Despite the historical ineffectiveness of this metric, the consensus among analysts in raising earnings estimates indicates a positive outlook for the stock.

Portfolio Pulse from

December 03, 2024 | 12:00 am